Recombinant Human HIF1A Protein，His

Hypoxia-inducible factor 1 alpha (HIF1A) is a crucial transcription factor that plays a significant role in cellular responses to oxygen deficiency, or hypoxia. Its importance emerged from studies linking HIF1A to various physiological and pathological processes, including metabolism, angiogenesis, and tumor progression. Under hypoxic conditions, HIF1A is stabilized and translocates to the nucleus, where it binds to hypoxia-responsive elements (HREs) in target genes, facilitating adaptive responses to low oxygen levels. Recent research has highlighted its potential as a therapeutic target in cancer treatment, where tumors exploit hypoxia to promote growth and resistance to therapies. Additionally, HIF1A's involvement in chronic diseases, such as cardiovascular diseases and metabolic disorders, has spurred interest in understanding its mechanisms and pathways. The study of HIF1A recombination protein focuses on deciphering its structure, function, and interaction with other cellular components, providing insights into its regulatory roles in various contexts. Advances in recombinant DNA technology have enabled the production of HIF1A fusion proteins, facilitating the investigation of its biological activities and the development of potential HIF1A-modulating drugs. This research is crucial for harnessing the therapeutic potential of targeting HIF1A in different diseases, aiming to improve clinical outcomes and pave the way for innovative treatment strategies.